PCOS, Endometriosis & Gynecologic Health • ICD-10-CM N81.3
Complete uterovaginal prolapse
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N81.3 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Complete uterovaginal prolapse Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within PCOS, Endometriosis & Gynecologic Health practice, Complete uterovaginal prolapse (ICD-10 N81.3) is stratified through iron repletion [Complete uterovaginal prolapse N81.3], pairing targeted symptom control with longitudinal Fasting Insulin & in Complete uterovaginal prolapse (N81.3: HbA1c) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code N81.3 categorizes Complete uterovaginal prolapse under PCOS, Endometriosis & Gynecologic Health.
- 3 Typical cash cost range: Differential triage of Complete uterovaginal prolapse (N81.3) utilizes iron repletion [Complete uterovaginal prolapse N81.3].
- 4 Top reported side effects / signs: Follow-up benchmark in Complete uterovaginal prolapse: maintaining Free & Total in Complete uterovaginal prolapse (N81.3: Testosterone + SHBG) within Sex-specific physiological range (N81.3).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Complete uterovaginal prolapse
What Is Complete uterovaginal prolapse?
Within PCOS, Endometriosis & Gynecologic Health practice, Complete uterovaginal prolapse (ICD-10 N81.3) is stratified through iron repletion [Complete uterovaginal prolapse N81.3], pairing targeted symptom control with longitudinal Fasting Insulin & in Complete uterovaginal prolapse (N81.3: HbA1c) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Complete uterovaginal prolapse (N81.3) features ovarian theca-cell hyperandrogenism in Complete uterovaginal prolapse (N81.3: amplified by hyperinsulinemia). therapeutic stabilization in ob/gyn & pcos is verified against Fasting Insulin & in Complete uterovaginal prolapse (N81.3: HbA1c).
Common Symptoms & Clinical Signs
- • Presentation of Complete uterovaginal prolapse (N81.3): irregular, infrequent, or in Complete uterovaginal prolapse (N81.3: absent ovulatory menstrual)
- • Secondary Complete uterovaginal prolapse clinical sign: severe pelvic cramping [Complete uterovaginal prolapse N81.3]
- • Symptom flares in Complete uterovaginal prolapse correlating with Free & Total in Complete uterovaginal prolapse (N81.3: Testosterone + SHBG) deviation outside Sex-specific physiological range (N81.3)
- • Functional ob/gyn & pcos impact requiring iron repletion [Complete uterovaginal prolapse N81.3] evaluation (N81.3)
Complete uterovaginal prolapse Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N81.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Free & Total in Complete uterovaginal prolapse (N81.3: Testosterone + SHBG) | Sex-specific physiological range (N81.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin & in Complete uterovaginal prolapse (N81.3: HbA1c) | Fasting insulin < 8 uIU/mL (N81.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC & Serum in Complete uterovaginal prolapse (N81.3: Ferritin (heavy bleeding)) | Ferritin > 50 ng/mL (N81.3) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Complete uterovaginal prolapse
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Generic • RxCUI 643066 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 86% | $1.1078 | $ 53.37 /mo |
| Pepcid Complete Dual Action Berry Flavor (Famotidine, Calcium Carbonate, Magnesium Hydroxide) Pepcid Complete Dual Action Berry Flavor • RxCUI 688892 | Histamine-2 Receptor Antagonist | 83% | $0.0992 | $ 15.64 /mo |
| Complete Dual Action (Famotidine, Calcium Carbonate and Magnesium Hydroxide) Complete Dual Action • RxCUI 283641-B42507321 | Histamine-2 Receptor Antagonist | 87% | $0.0992 | $ 15.64 /mo |
| Cabotegravir and Rilpivirine Cabenuva • RxCUI 2475415 | FDA Prescription Therapeutic Agent | 79% | $1.3100 | $ 61.56 /mo |
| Naloxone Hydrochloride Narcan, Zimhi • RxCUI 1191222 | Opioid Antagonist | 89% | $11.3001 | $ 61.36 /mo |
| Dolutegravir Sodium and Rilpivirine Hydrochloride Juluca • RxCUI 1989500 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 86% | $121.5738 | $ 185.00 /mo |
| Nicotine Patches Nicotine Patches Generic • RxCUI 2728721 | Cholinergic Nicotinic Agonist | 88% | $1.6017 | $ 73.37 /mo |
| Valproic Acid Depakene • RxCUI 1099681 | Anti-epileptic Agent | 92% | $0.0332 | $ 9.14 /mo |
| Flumazenil Flumazenil Generic • RxCUI 204508 | Benzodiazepine Antagonist | 87% | $0.9941 | $ 48.76 /mo |
| Bictegravir/Lenacapavir Bixlenvo • RxCUI 2750177 | Human Immunodeficiency Virus 1 Capsid Inhibitor | 81% | $0.3300 | $ 21.87 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Complete uterovaginal prolapse)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete: What a 1,382-Participant Study Found Tenapanor was observed to improve abdominal symptoms independent of its effect on bowel symptoms in adults with IBS-C. Digestive diseases (Basel, Switzerland) • 2025-01-15 • Phase III Randomized Trial | N = 1,382 | 96/100 | PMID 39701047 ↗ |
| Can This Approach Help? Inside the Latest Research on Patient-reported outcomes with adjuvant nivolumab versus placebo after complete Patients with resected stage IIB/C melanoma treated with adjuvant nivolumab demonstrated stable HRQoL and minimal bother from side effects. European journal of cancer (Oxford, England : 1990) • 2025-05-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40139004 ↗ |
| Can This Approach Help? Inside the Latest Research on Early disease intervention with guselkumab in psoriasis leads to a higher rate of Guselkumab efficacy was consistent across subpopulations, on the skin and systemically. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37262309 ↗ |
| Can This Approach Help? Inside the Latest Research on Type-I-error rate inflation in mixed models for repeated measures caused by However, the results of this simulation study rather underestimate the true T1E rate inflation. Pharmaceutical statistics • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37519010 ↗ |
| Can This Approach Help? Inside the Latest Research on Budesonide as induction therapy for incomplete microscopic colitis: A randomised, Budesonide decreased the frequency of soft or watery stools and improved the patients' quality of life significantly in MCi, but the primary endpoint was not met due to the low sample size (type 2 error). United European gastroenterology journal • 2021-09-15 • Phase III Randomized Trial | N = 44 | 88/100 | PMID 34414678 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Complete uterovaginal prolapse Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Complete uterovaginal prolapse community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Complete uterovaginal prolapse.